NB Health Laboratory (NBHL) specializes in the development of GPCR-targeted antibodies, leveraging its proprietary MoGRAA® Discovery Engine. This innovative platform is designed to enhance drug discovery by efficiently generating functional monoclonal antibodies that specifically bind to G-protein coupled receptors (GPCRs). The MoGRAA® Discovery Engine addresses the challenges associated with traditional GPCR-targeted drug development, which has seen a decline in the success rates of low molecular weight compounds. By focusing on the unique properties of GPCRs, NBHL aims to create a new class of therapeutic antibodies that can effectively target various diseases, including autoimmune disorders, fibrosis, and severe viral infections.

The technologies employed by NBHL not only facilitate the identification and optimization of antibodies but also allow for the simultaneous development of multiple therapeutic candidates. The MoGRAA® platform is particularly adept at producing antibodies against various GPCR subtypes, including those with unknown structures. This capability positions NBHL at the forefront of GPCR-targeted drug discovery, enabling the company to explore new therapeutic avenues and address unmet medical needs. Through its commitment to research and development, NBHL is dedicated to advancing its pipeline of GPCR-targeted antibodies toward clinical application.

Japan

NBHL is committed to discovering First-In-Class medicines for the unmet medical needs with the sophisticated drug discovery platforms ( Monoclonal Antibody for GPCR and Small compounds ). We are looking for the pharmaceutical partners to develop the following projects. We are available for the project-based Drug discovery alliance, using our drug discovery platforms powered by PerkinElmer, and Biotech companies.

NB Health Laboratory

Company Details